GlobeNewswire

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
03/12/2025
– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site- [...]
March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer
03/12/2025
Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management team HOUSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging [...]
Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
03/12/2025
Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025 CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the [...]
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
03/12/2025
Company advances JOTROL ™ into Phase 2a Parkinson’s trial, launches Nugevia ™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]
Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)
03/12/2025
Preclinical in vivo data demonstrate hyper-precise mechanism directly targets the disease-causing mRNA repeats leading to correction of splicing defects and reversal of myotonia Oral administration of lead drug [...]
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
03/12/2025
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
DIMERx Appoints Lee S. Simon, MD as Chief Advisor for Clinical Development & Regulatory Strategy
03/12/2025
Veteran FDA and Industry Leader to Guide Late-Stage Programs, Including First-In-Class Non-Addictive Analgesic DMX-101 SAN FRANCISCO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc. (“DIMERx”), a clinical-stage [...]
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
03/12/2025
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/12/2025
BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
Catheter Precision Secures Tender From Leading Hospital in Hungary
03/12/2025
FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is [...]
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
03/12/2025
Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees This latest approval will help [...]
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
03/12/2025
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in [...]
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
03/12/2025
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’ [...]
Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies
03/12/2025
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome [...]
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
03/12/2025
SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology
03/12/2025
Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCC The combination continued to show clinically meaningful survival improvement [...]
BetaGlue Therapeutics étend son essai clinique en Italie après avoir obtenu l’autorisation du ministère de la Santé italien pour mener son étude clinique sur le cancer du pancréas localement avancé non résécable (uLA-PDAC)
03/12/2025
MILAN, 03 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société d’oncologie en phase clinique développant une solution innovante de radiothérapie pour le traitement ciblé [...]
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
03/12/2025
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the [...]
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
03/12/2025
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum